CAI News & Events

An increase of approximately 116% from last year. Completed approximately 52,700 clinical therapy selection cases, an increase of approximately 20% and consisting of approximately 44,150 MI Profile cases and approximately 8,550 Caris Assure cases.

An increase of approximately 94% from last year. Completed approximately 199,300 clinical therapy selection cases, an increase of 22% and consisting of approximately 170,300 MI Profile cases and approximately 29,000 Caris Assure cases.

Caris Life Sciences announced a partnership with Everlywell, a digital health company. Caris and Everlywell are partnering to launch Caris Detect, Caris' forthcoming Multi-Cancer Early Detection blood-based screening assay, through Everlywell's platform. Caris Detect utilizes comprehensive whole genome sequencing technology to identify multiple cancer types by analyzing molecular signals circulating in the bloodstream. Caris expects to launch the Caris Detect assay in the first half of 2026.